Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans

Intensive Care Med. 2003 Feb;29(2):337. doi: 10.1007/s00134-002-1605-y. Epub 2003 Jan 15.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Anti-Infective Agents / therapeutic use*
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • IgA Vasculitis / blood
  • IgA Vasculitis / drug therapy*
  • IgA Vasculitis / immunology
  • Inflammation
  • Male
  • Meningococcal Infections / blood
  • Meningococcal Infections / drug therapy*
  • Meningococcal Infections / immunology
  • Protein C / therapeutic use*
  • Recombinant Proteins / therapeutic use*
  • Severity of Illness Index
  • Shock, Septic / blood
  • Shock, Septic / drug therapy*
  • Shock, Septic / immunology
  • Treatment Outcome

Substances

  • Anti-Infective Agents
  • Anti-Inflammatory Agents, Non-Steroidal
  • Fibrinolytic Agents
  • Protein C
  • Recombinant Proteins
  • drotrecogin alfa activated